New drug combo targets tough cancers in early trial

NCT ID NCT06545942

Recruiting now Disease control Sponsor: MOMA Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This early-phase study tests a new oral drug called MOMA-313, alone or with another drug (olaparib), in people with advanced solid tumors that have certain DNA repair flaws. The main goals are to check safety and find the right dose. About 220 adults with cancers like prostate, pancreas, breast, or ovarian cancer are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MOMA-313 (a drug taken by mouth) and olaparib (a PARP inhibitor taken by mouth)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have specific DNA repair problems.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing, not on proving the drug works. It is small and may not lead to an approved treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm DNA repair disease malignant pancreatic neoplasm metastatic malignant neoplasm metastatic prostate carcinoma Neoplasm Metastasis ovarian cancer pancreatic ductal adenocarcinoma pancreatic neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR BREAST CANCER HOMOLOGOUS RECOMBINATION DEFICIENCY METASTATIC SOLID TUMOR OVARIAN CANCER PANCREAS CANCER PROSTATE CANCER

Contacts and locations

Locations

Investigative Site #101
RECRUITING

La Jolla, California, 92093, United States
Investigative Site #102
RECRUITING

Nashville, Tennessee, 37203, United States
Investigative Site #103
RECRUITING

New York, New York, 10016, United States
Investigative Site #104
RECRUITING

Lake Mary, Florida, 32746, United States
Investigative Site #105
COMPLETED

San Antonio, Texas, 78229, United States
Investigative Site #106
RECRUITING

New York, New York, 10065, United States
Investigative Site #107
COMPLETED

Myrtle Beach, South Carolina, 29572, United States
Investigative Site #108
RECRUITING

Goodyear, Arizona, 85338, United States
Investigative Site #109
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Investigative Site #110
RECRUITING

St Louis, Missouri, 63110, United States
Investigative Site #111
COMPLETED

San Francisco, California, 94143, United States
Investigative Site #112
COMPLETED

Fairfax, Virginia, 22031, United States
Investigative Site #113
RECRUITING

London, United Kingdom
Investigative Site #114
RECRUITING

Barcelona, Spain
Investigative Site #115
RECRUITING

Madrid, Spain
Investigative Site #116
RECRUITING

Barcelona, Spain
Investigative Site #117
RECRUITING

Manchester, United Kingdom
Investigative Site #118
RECRUITING

Newcastle upon Tyne, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.